Click Therapeutics, Inc.’s Post

#AkeroTherapeutics Inc shares lost roughly two-thirds of their value Tuesday morning after the company released a disappointing update on its fatty liver disease treatment.  A study found that just 22% to 24% of the patients with compensated cirrhosis due to NASH (nonalcoholic steatohepatitis) who received Akero’s treatment efruxifermin saw at least a one-stage improvement in liver fibrosis, according to a statement.  Shares of Akero plummeted 68% to $15.57.  On the positive side, roughly 60% of patients who received efruxifermin had NASH resolution after 36 weeks, compared with 26% of those who received a placebo. That represents, “the highest response rates reported to date for NASH resolution in this patient population,” the company said. “We set a high bar with the primary endpoint after only 36 weeks of treatment,” CEO Andrew Cheng said in a statement. More at #Proactive #ProactiveInvestors http://ow.ly/t6uR104XlA4

The past webinar ”Underneath the lost kilos” from Antaros Medical was a great success. Next webinar with these top-notch panelist is now open for registration. Sign up for this interesting discussion! #clinicalimaging #antarosmedical #antarostracer #clinicaltrials #drugdevelopment

📢 The FDA has approved the Benlysta® (belimumab) autoinjector for at-home use for kids five and older with active systemic #lupus erythematosus (SLE) who are receiving standard therapy. Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It was previously available (for children five and older) only through infusion in a hospital or clinic. The medicine can now be administered at home via an autoinjector once a week for children who weigh 40 kg or more (or once every two weeks for children who weigh 15 kg-39 kg). 💜 Lupus advocates noted this new option may help reduce the burden for families who previously had to travel to a hospital, miss days of school, and take time away from work. For more info: https://lnkd.in/eZr6-Qp4 #LupusAwarenessMonth #pedsrheum #Rheumatology #autoimmune

Our Teva Pharmaceuticals and Sanofi team rocking the purple onsite at #DDW2024 showing their support for World Inflammatory Bowel Disease (IBD) day and the IBD patient community. IBD, a broad term that refers to chronic inflammation in the GI tract, like Crohn’s disease and ulcerative colitis, can make everyday life challenging. It seems fortuitous that #WorldIBDDay2024 falls during Digestive Disease Week 2024, a moment in time when key opinion leaders in gastroenterology come together to discuss both emerging research and the critical unmet need for those managing IBD. I’m ever-inspired by the curiosity and passion of physician-scientists in their relentless commitment to developing novel treatments for conditions that make everyday life challenging for people living with chronic medical conditions and associated symptoms. With no cure currently existing and globally ~4.9 million cases of IBD identified , now more than ever it is important to continue supporting further dialogue around new and novel treatments for IBD. If you can, I encourage you to join us in wearing purple today and join in on the conversation on IBD. #IBDhasnoborders #TogetherWeCanHelpPatients #TevaPharm #Sanofi #InnovativeMedicines #WorldIBDDay Dalbir Dhiraj Natalie Dow Beryl Ojwang Marla Hochfeld Azhar Choudhry, MD, MBA Carol J. Ou, PharmD, RPh Rochelle Yang Hadas Barkay Lilian Ibrahim @Gordon Raphael Sudeep Kundu Nathalie Magnus, MSc, PhD Tessa Hemrika @Salvatore Badalamenti Chris Soria, PharmD Shashank Rohatagi Dikla Gutman Rajiv Balyan

This article, published in the latest European Biopharmaceutical Review issue, provides great insights from Ivo Timmermans and Dan Gelvan on maximising the opportunities and navigating the challenges of developing a first-in-class therapy. #PlecoTherapeutics #Firstinclass #Healthcareinnovation #EBRMagazine

One week after the launch of its Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis patients, our portfolio company NMD Pharma A/S achieves today a major milestone in another key indication ⬇️ NMD Pharma A/S has just received IND clearance from the FDA to start its Phase 2 Clinical Trial with NMD670 in Charcot-Marie-Tooth disease (CMT Type 1 & Type 2) 👏 Charcot-Marie-Tooth disease is a highly debilitating condition with no cure or approved medicines yet available for patients. Results from the ESTABLISH observational study highlight neuromuscular junction transmission deficits as a previously unrecognized disease characteristic in CMT. This makes NMD Pharma A/S confident that NMD670 has the potential to work within the skeletal muscles to improve and maintain clinically meaningful benefits for this underserved group affected by the disease. By the end of 2024, NMD Pharma A/S will have three ongoing Phase 2 trials using its skeletal muscle activation enhancing therapy in rare neuromuscular diseases (spinal muscular atrophy (SMA), generalised myasthenia gravis (gMG) and Charcot-Marie-Tooth (CMT)). Read more 👉 https://lnkd.in/eyPUFzzy #FasterForThePatient #Innovation #RareDisease #biopharma #neuromusculardisease

Evidence supporting reimbursement of digital therapeutics >> https://lnkd.in/et_bEpJy Digital therapeutics are evidence-based therapeutic interventions, often developed in combination with a device and/or therapeutic agent, that are designed to prevent, manage, or treat a variety of medical conditions and address challenges such as medication adherence and disease control. In this update, we discuss evidence generation to support optimal reimbursement of digital therapeutics. https://lnkd.in/et_bEpJy #HEOR #MarketAccess

Evidence supporting reimbursement of digital therapeutics >> https://lnkd.in/et_bEpJy Digital therapeutics are evidence-based therapeutic interventions, often developed in combination with a device and/or therapeutic agent, that are designed to prevent, manage, or treat a variety of medical conditions and address challenges such as medication adherence and disease control. In this update, we discuss evidence generation to support optimal reimbursement of digital therapeutics. https://lnkd.in/et_bEpJy #HEOR #MarketAccess

The FDA has launched the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) program. The program aims to expedite research and development for rare diseases by helping companies navigate clinical development challenges, such as study design and patient population. Participating companies will benefit from FDA guidance and advice, aiming to accelerate the regulatory process for new rare disease therapies. Read More: https://lnkd.in/dTk76rWQ #ActuReal #Healthcare #Patientcare #Trendingnews

Inflammatory bowel disease (IBD) is a complex disease that requires a high-level of coordinated care. Today, the American Gastroenterological Association (AGA) announced that it published a white paper on the future of IBD care. Current barriers to care are highlighted, and the AGA calls for greater collaboration among the healthcare community, insurers, pharmaceutical companies and legislators to improve care for the millions of patients living with IBD in the US. We applaud the great work the AGA is doing to highlight these important issues that effect so many patients and families. https://lnkd.in/eSWgMFFa #gastroenterology #inflammatoryboweldisease #ibdawareness